NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease
- PMID: 25281696
- PMCID: PMC4252745
- DOI: 10.1158/1078-0432.CCR-14-0479
NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease
Abstract
Purpose: Not all natural killer (NK) cells are equally cytotoxic against leukemia because of differences in receptor gene content and surface expression. We correlated NK cell genotype and phenotype at diagnosis of childhood acute lymphoblastic leukemia (ALL) with minimal residual disease (MRD) after induction chemotherapy.
Experimental design: The NK cells and leukemia blasts of 244 patients were analyzed at diagnosis by killer-cell immunoglobulin-like receptor (KIR) typing and immunophenotyping. The results were correlated statistically with postinduction MRD status.
Results: The odds of being MRD positive in patients with KIR telomeric (Tel)-A/B genotype were 2.85 times the odds in those with Tel-A/A genotype (P = 0.035). MRD-positive patients were more likely to have KIR2DL5A (P = 0.006) and expressed less activating receptor NKp46 and FASL on their NK cells (P = 0.0074 and P = 0.029, respectively). The odds of being MRD positive increased by 2.01-fold for every percentage increase in NK cells expressing KIR2DL1 in the presence of HLA-C2 ligand (P = 0.034). The quantity of granzyme B inhibitor PI-9 in the leukemia blasts was greater in patients who were MRD positive (P = 0.038). Collectively, five NK cell-related factors (Tel-B-associated KIR2DL5A, NKp46, FASL, granzyme B, and PI-9) are strongly associated with MRD positivity at the end of induction with 100% sensitivity and 80% specificity.
Conclusions: Our data support the hypothesis that NK cells with a strong effector phenotype in the setting of decreased leukemia resistance are associated with better leukemia control.
©2014 American Association for Cancer Research.
Conflict of interest statement
Conflicts of Interest Disclosures:
Erin Sullivan, Sima Jeha, Guolian Kang, Barbara Rooney, Martha Holladay, Rafijul Bari, Sarah Schell, MaCal Tuggle, and Wing Leung have no conflicts of interest to disclose.
Figures


Similar articles
-
Association of killer immunoglobulin-like receptor genotypes and haplotypes with acute lymphoblastic leukemia risk.Innate Immun. 2025 Jan-Dec;31:17534259251314774. doi: 10.1177/17534259251314774. Innate Immun. 2025. PMID: 39828905 Free PMC article.
-
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.Haematologica. 2014 Jul;99(7):1248-54. doi: 10.3324/haematol.2013.101931. Epub 2014 Mar 21. Haematologica. 2014. PMID: 24658822 Free PMC article.
-
Genetic associations of killer immunoglobulin like receptors and class I human leukocyte antigens on childhood acute lymphoblastic leukemia among north Indians.Hum Immunol. 2016 Jan;77(1):41-46. doi: 10.1016/j.humimm.2015.10.009. Epub 2015 Oct 21. Hum Immunol. 2016. PMID: 26472014
-
Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):359-69. doi: 10.1002/cyto.b.21101. Epub 2013 Jun 26. Cytometry B Clin Cytom. 2013. PMID: 23757107 Review.
-
Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.Crit Rev Oncog. 2017;22(5-6):559-567. doi: 10.1615/CritRevOncog.2017020588. Crit Rev Oncog. 2017. PMID: 29604931 Review.
Cited by
-
Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.Front Immunol. 2024 Jan 17;14:1325255. doi: 10.3389/fimmu.2023.1325255. eCollection 2023. Front Immunol. 2024. PMID: 38299154 Free PMC article. Review.
-
The Fetal-to-Adult Hematopoietic Stem Cell Transition and its Role in Childhood Hematopoietic Malignancies.Stem Cell Rev Rep. 2021 Dec;17(6):2059-2080. doi: 10.1007/s12015-021-10230-x. Epub 2021 Aug 23. Stem Cell Rev Rep. 2021. PMID: 34424480 Free PMC article. Review.
-
Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives.Front Immunol. 2022 Jun 13;13:921894. doi: 10.3389/fimmu.2022.921894. eCollection 2022. Front Immunol. 2022. PMID: 35769486 Free PMC article. Review.
-
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.Oncotarget. 2017 Jul 25;8(30):49548-49563. doi: 10.18632/oncotarget.17747. Oncotarget. 2017. PMID: 28548938 Free PMC article.
-
Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges.Front Immunol. 2023 Jan 11;13:1044946. doi: 10.3389/fimmu.2022.1044946. eCollection 2022. Front Immunol. 2023. PMID: 36969979 Free PMC article. Review.
References
-
- Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795–9. - PubMed
-
- Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99:3661–7. - PubMed
-
- Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007;109:323–30. - PubMed
-
- Nasrallah AG, Miale TD. Decreased natural killer cell activity in children with untreated acute leukemia. Cancer Res. 1983;43:5580–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous